-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HauCsIKNqKd2z1oRTVmCL0aqjya4CdwEGQpTDkQZ+sUiNQLqbV1VHzEFHF1DlXOK fh3NoXNxulgynx4KmFRX9w== 0000922423-98-000092.txt : 19980203 0000922423-98-000092.hdr.sgml : 19980203 ACCESSION NUMBER: 0000922423-98-000092 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19980116 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19980202 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: HYBRIDON INC CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-27352 FILM NUMBER: 98519600 BUSINESS ADDRESS: STREET 1: 620 MEMORIAL DR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6175287000 MAIL ADDRESS: STREET 1: 620 MEMORIAL DRIVE STREET 2: 620 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 CURRENT REPORT - -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------------------------ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 1998 0-27352 (Commission File Number) ------------------------------ HYBRIDON, INC. (Exact name of registrant as specified in its charter) Delaware 3072298 - -------------------------------------------------------------------------------- (State of Incorporation) (IRS Employer Identification Number) 620 Memorial Drive, Cambridge, Massachusetts 02139 - -------------------------------------------------------------------------------- (Address of registrant's principal executive office) (617) 528-7000 - -------------------------------------------------------------------------------- (Registrant's telephone number) ------------------------------ - -------------------------------------------------------------------------------- ITEM 5. Other Events On January 23, 1998, Hybridon, Inc. (the "Company") issued a press release announcing that the Company has satisfied the 20 Unit minimum offering threshold for the private placement, the commencement of which was previously announced by the Company. A copy of the release has been filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits (c) Exhibits. Exhibit Number Title - -------------- ----- 99.1 Press Release dated January 23, 1998 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HYBRIDON, INC. By: /s/ E. ANDREWS GRINSTEAD, III ----------------------------- Name: E. Andrews Grinstead, III Title: Chairman of the Board, President and Chief Executive Officer Date: February 2, 1998 EX-99.1 2 PRESS RELEASE FOR IMMEDIATE RELEASE Exhibit 99.1 ------------ Company Press Release SOURCE: Hybridon, Inc. Hybridon Announces Satisfaction of the Minimum 20 Unit Private Placement Offering Amount CAMBRIDGE, Mass., Jan. 23/PRNewswire/-- Hybridon, Inc. (OTC Bulletin Board: HYBN - - news) today announced it has satisfied the 20 Unit minimum offering threshold for the private placement announced by the Company yesterday. Hybridon, headquartered in Cambridge, Massachusetts, is engaged in the discovery and development of genetic medicines for the treatment of certain diseases, based primarily on antisense technology. Antisense technology attempts to use synthetic segments of DNA and RNA to stop the production of disease-associated proteins by interacting at the genetic level with target strands of messenger RNA. SOURCE: Hybridon, Inc. -----END PRIVACY-ENHANCED MESSAGE-----